Ionis Pharmaceuticals
IONS
309 hedge funds and large institutions have $5.2B invested in Ionis Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 68 funds opening new positions, 88 increasing their positions, 90 reducing their positions, and 38 closing their positions.
89.66% more ownership
Funds ownership: 0% → 89.66% (+90%)
79% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 38
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
32% more capital invested
Capital invested by funds: $3.94B → $5.2B (+$1.26B)
9% more funds holding
Funds holding: 283 → 309 (+26)
6% more call options, than puts
Call options by funds: $79M | Put options by funds: $74.5M
2% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 90
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$115M |
| 2 |
ClearBridge Investments
New York
|
+$48.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$34.3M |
| 4 |
O
OppenheimerFunds
New York
|
+$21M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$63.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$32.1M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
-$29.6M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$25.8M |
| 5 |
LS
Livforsakringsbolaget Skandia
Stockholm,
Sweden
|
-$15.4M |
IONS Hedge Fund Activity: Q4 2016 in Review
309 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2016, worth a combined $5.2B — up 32% from $3.94B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new IONS positions and 38 closed out — a net gain of 30 holders — while 88 added to existing stakes and 90 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $115M. The largest seller was Millennium Management, cutting an estimated $63.4M.
- 309 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2016, up from 283 in Q3 2016.
- Funds reported $5.2B of Ionis Pharmaceuticals stock for Q4 2016, up 32% quarter-over-quarter.
- 68 funds opened new Ionis Pharmaceuticals positions in Q4 2016 and 38 closed out, a net change of +30 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2016 was Wellington Management Group, an estimated $115M added.
- The largest Ionis Pharmaceuticals seller in Q4 2016 was Millennium Management, an estimated $63.4M sold.
Based on aggregated 13F filings for Q4 2016.